Background {#Sec1}
==========

Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor, most commonly reported to occur in the lungs, liver, and bone, along with many other sites throughout the body \[[@CR1]\]. The etiology of EHE is unknown. Previously, EHE was recognized as an intermediate-risk disease, classified between angioma and angiosarcoma \[[@CR2]\]; however, in the fourth revision of the World Health Organization classification, EHE was described as a malignant vascular tumor, similar to angiosarcoma \[[@CR3]\].

EHE of the thyroid is very rare, and only three cases have been reported to date in the English literature. Here, we describe a patient with EHE of the thyroid who underwent successful resection.

Case presentation {#Sec2}
=================

A 74-year-old woman was referred to our hospital because of a nodule in the right lobe of the thyroid. The nodule had been found during a medical examination performed 3 years ago, but she did not undergo a detailed examination at the local hospital at that time. On physical examination, a palpable and hard nodule of approximately 2 cm in size was noted in the right side of her neck. Results of the blood examination were normal, except for mildly increased thyroglobulin (142 ng/mL) and antithyroglobulin antibody levels (59.7 IU/mL). Ultrasonography and computed tomography showed a right thyroid nodule with calcification. The nodule had no signs of extrathyroidal invasion and measured 21 mm in diameter. The lymph nodes of the neck were not swollen (Fig. [1](#Fig1){ref-type="fig"}). The nodule was diagnosed as an indeterminate lesion by fine needle aspiration cytology. The fine needle aspiration smears showed spindle-shaped cells with prominent nucleoli and nuclear inclusion. The intercellular space was metachromatic on Giemsa staining (Fig. [2](#Fig2){ref-type="fig"}). Taken together, these findings suggested a hyalinizing trabecular adenoma, granulomatous lesion, papillary carcinoma, or poorly differentiated carcinoma.Fig. 1Characteristics of the thyroid nodule. Computed tomography scan showing the right thyroid nodule with calcification (*arrow*) (**a**). The nodule is enhanced and shows no signs of extrathyroidal invasion (*arrow*) (**b**). Ultrasonogram showing the right thyroid nodule (21 mm in diameter) with calcification (*arrow*) (**c**). Macroscopically, a well-circumscribed mass in the right lobe of the thyroid is observed (**d**) Fig. 2Fine needle aspiration smears. Spindle-shaped cells are observed, with prominent nucleoli and nuclear inclusion (Papanicolaou stain, ×400) (**a**). The intercellular space is metachromatic (Giemsa stain, ×100) (**b**)

We decided to treat this nodule as thyroid cancer. Right thyroid lobectomy and central neck dissection were performed. Macroscopically, a well-circumscribed mass in the right lobe of the thyroid was observed. Histologic evaluation of the thyroid nodule showed multinodular proliferation of oval to polygonal-shaped epithelioid cells with oval nuclei and eosinophilic cytoplasm arranged in sheet- or cord-like patterns, accompanied by fibrous stroma and marked osseous metaplasia. Nuclear atypia was mild, and mitosis was not prominent. Results of the immunohistochemical staining showed that these areas were partially positive for cytokeratin, cluster of differentiation (CD)34, and factor VIII; diffusely positive for vimentin; and negative for thyroglobulin, thyroid transcription factor-1, smooth muscle actin, desmin, S100, CD31, CD68, and CD163 (Fig. [3](#Fig3){ref-type="fig"}). These findings were suggestive of EHE.Fig. 3Histological findings. Multinodular proliferations, composed of comparatively rich spindle cells with nuclear blebs, are observed between the trabecular bone structures. Intracytoplasmic vacuoles are also seen (**a** hematoxylin and eosin stain, ×10; **b** hematoxylin and eosin stain, ×100). Immunohistochemically, the tumor cells were positive for cluster of differentiation (CD)34 and factor VIII (**c** factor VIII, ×100; **d** CD34, ×100)

Postoperatively, the patient's thyroglobulin level fluctuated inconsistently (range, 11--292 ng/mL), as did the antithyroglobulin antibody level, although it remained positive. The mild elevation of the preoperative and postoperative thyroglobulin levels might have been caused by chronic thyroiditis. The patient has been followed-up for 3 years and has had no signs of recurrence postoperatively.

Conclusions {#Sec3}
===========

EHE is a rare disease, first described by Weiss et al. in 1982 \[[@CR2]\]. The authors classified it as a vascular tumor, showing the same histological findings, but reported it as a different disease in each organ (e.g., intravascular bronchioloalveolar tumor of the lung) \[[@CR4]\]. The 2002 World Health Organization classification changed the classification of EHE from an intermediate to malignant tumor, because some malignant clinical cases had been reported in patients with EHE. EHE most commonly presents in the liver, lung, and bone \[[@CR5]\]. The characteristics of EHE in these common sites are shown in Table [1](#Tab1){ref-type="table"}. In addition, Table [2](#Tab2){ref-type="table"} summarizes the reported EHE cases from various, rare sites of the body.Table 1Characteristics of epithelioid hemangioendothelioma (EHE) in the liver, lungs, soft tissues, and bone (common presentations)Site \[ref\]SexMulticentricMetastasisManagementSurvival rate (5 years)Prognostic factorsTreatmentRate (%)SiteLiver\
\[[@CR14]--[@CR19]\]M \< F87%36.6Lungs, peritoneum, lymph nodes, boneTransplantation, resection, medication, radiotherapy, embolization41Extrahepatic disease, vascular invasionChemotherapy (doxorubicin, cisplatin, 5FU), targeted therapy (sorafenib, pazopanib), IFN α-2b, thalidomide, lenalidomideLung\
\[[@CR1], [@CR20]--[@CR23]\]M \< F91%50.5Liver, pleura, lymph nodesLung resection, medication60Hemoptysis, pleural effusion, anemia, thoracic symptomsChemotherapy (carboplatin, paclitaxel), targeted therapy (bevacizumab, pazopanib), IFN α-2b, thalidomide, lenalidomideSoft tissue\
\[[@CR10], [@CR24]\]M \< F4%22Lungs, lymph nodes, liver, boneSurgical resection, chemotherapy, radiotherapy81Mitotic activity, sizeNDBone\
\[[@CR25]--[@CR27]\]M \> F\>50%NDUncommonWide surgical resection, limited surgery, radiofrequency ablation, radiotherapy92 (10 years)Visceral involvement*M* male, *F* female, *5FU* 5-fluorouracil, *IFN* interferon, *ND* not determined Table 2Summary of previously reported cases of epithelioid hemangioendothelioma (EHE) occurring in rare sitesAuthor \[ref\]SiteTreatmentMetastasis/reccurenceOutcome (follow-up period)Barger \[[@CR28]\]BrainResection(this case), chemotherapy, radiotherapy, gamma knife, sunitinib(−)/NDAlive (1 month)Sancheti \[[@CR29]\]HypopharynxExcision(−)/(−)Alive (1 year)Boscaino \[[@CR30]\]LarynxResectionND/NDNDPigadas \[[@CR31]\]Parotid salivary glandParotidectomy(−)/(−)Alive (18 months)Moulai \[[@CR32]\]HeartChemotherapy, cardiac transplantation(−)/(+) 2 yearsAlive (10 years)Traverse \[[@CR33]\]AortaResection(−)/NDNDCharette \[[@CR34]\]VeinResection(−)/(−)Alive (18 months)Versaci \[[@CR35]\]StomachResection(−)/(−)Alive (8 months)Ratan \[[@CR36]\]Greater omentumResection(−)/(−)Alive (6 years)Bozkurt \[[@CR37]\]Adrenal glandLaparoscopic excision(−)/(−)Alive (6 months)Tolkach \[[@CR38]\]KidneyNephrectomy, sunitinib(−)/(+) 2 mDead (33 months)Liu \[[@CR39]\]BladderTransurethral resection(−)/(−)Alive (6 months)Elhosseiny \[[@CR40]\]PenisLocal excision(−)/(−)Alive (ND)Illueca \[[@CR41]\]OvaryResection(−)/(−)Alive (1 year)

Especially, EHE of the thyroid is extremely rare \[[@CR6]--[@CR9]\], with only one case reported in the Japanese literature \[[@CR9]\], along with three in the English literature \[[@CR6]--[@CR8]\]. These cases and our present case are summarized in Table [3](#Tab3){ref-type="table"}.Table 3Cases of thyroid epithelioid hemangioendothelioma (EHE)Author/year \[ref\]Age (years)SexThyroid tumorSurgical procedureMetastasisAdjuvant therapyRecurrenceOutcome (follow-up period)LocationSize (mm)ThyroidNeck dissectionFujiwara/1998 \[[@CR9]\]56MLeft lobe30LobectomyLeft lateralLymph nodeRadiation(−)Alive (11 months)Siddiqui/1998 \[[@CR6]\]44FRight lobe37LobectomyUnknownUnknown(−)(−)Alive (24 months)Hassan/2005 \[[@CR7]\]73FRight lobe80Total thyroidectomyUnknownUnknownIFN-α(+) 9 monthsDead (13 months)Shah/2016 \[[@CR8]\]35FLeft lobe27Total thyroidectomyLeft lateralLymph nodePlans for radiation and chemotherapy(−)Alive (4 months)Our case/201674FRight lobe21LobectomyCentral(−)(−)(−)Alive (36 months)*M* male, *F* female

Of note, only one of the five patients was male (20%), which is in accordance with previous studies on EHE of other organs, in which most patients were women (male to female ratio, 1:4) \[[@CR1]\]. There was no predominance in age (range, 35--74 years) or tumor size (range 2.1--8 cm), but all patients had a single nodule of the thyroid. On the other hand, EHE of other organs associated with multiple organ involvement in 36% of cases \[[@CR5]\].

There have been several discussions on the prognostic factors of EHE, such as the presence of pulmonary lesions, multiorgan involvement, age, and sex \[[@CR1]\]. In addition, mitotic activity (\>3 mitotic figures/50 high-power fields) and size (\>3.0 cm) have been reported as risk factors for mortality in cases of EHE of the soft tissues \[[@CR10]\]. Although the thyroid EHE patient with the largest tumor (80 mm) died 13 months after the diagnosis \[[@CR7]\], the other patients, whose tumor sizes were all \<4 cm, had uneventful outcomes \[[@CR6], [@CR8], [@CR9]\].

There is no standard treatment for EHE, although curative resection has been reported as a successful treatment with good outcomes \[[@CR1]\]. All five patients with thyroid EHE underwent surgery. For this site, total resection can be relatively easily performed, whereas this treatment is unlikely to be performed for EHEs of other organs such as the liver, bone, and lungs. However, it is difficult to maintain a sufficient surgical margin in cases of large thyroid tumors. Our patient had the smallest tumor of the five cases, and no signs of adhesion, extrathyroidal extension, and lymph node metastasis. As mentioned above, the previously reported patient with the largest tumor experienced local recurrence and died. That tumor showed adhesion, whereas pathologically, there was no evidence of a residual tumor \[[@CR7]\]. These findings suggest that tumor size is likely an important factor for the effectiveness of curative resection for thyroid EHE. Further studies are needed to determine the optimal surgical margin and whether lymph node dissection is sufficient for curative surgery. Moreover, two patients received radiation therapy because of lymph node metastasis. Radiation therapy may be effective to control local recurrences; however, this could not be confirmed, because the follow-up periods in the past cases were short.

Finally, the presence of CAMTA1-WWTR1 gene fusion in EHE was recently demonstrated \[[@CR11]\]. This abnormality has been reported in the majority of EHEs at various anatomical sites, while it is absent in other epithelioid vascular tumors \[[@CR11]--[@CR13]\]. It was also confirmed in one case of thyroid EHE \[[@CR8]\]. Therefore, fluorescence in situ hybridization analysis to detect CAMTA-WWTR1 fusion may become a definite tool for the diagnosis of EHE in the future.

In conclusion, EHE of the thyroid is an extremely rare disease. Its clinical course varies, and the prognostic factors are unclear. Curative resection may be an effective treatment, but surgical issues such as the appropriate extent of the surgical margin and use of lymph node dissection remain to be clarified. Further studies are needed to analyze the etiology of EHE and to determine the optimal treatment.

CD

:   Cluster of differentiation

EHE

:   Epithelioid hemangioendothelioma

Authors' contributions {#FPar1}
======================

MO drafted the manuscript. YK and MO performed the surgery and postoperative management. YK and TU revised the manuscript. TU and YO performed the pathological diagnosis. All authors read and approved the final manuscript.

Authors' information {#FPar2}
====================

MO and YK are surgeons at the Department of Breast and Endocrine Surgery, Nagano Matsushiro General Hospital. YK is the general director of Nagano Matsushiro General Hospital. TU is an associate professor at the Department of Laboratory Medicine, Shinshu University School of Medicine. YO is a professor at the Department of Anatomic Pathology, Pathological Sciences, Kyushu University.

Competing interests {#FPar3}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar4}
=======================

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
